Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

Cutsem, Eric van; Tempero, Margaret A.; Sigal, Darren; Oh, Do-Youn; Fazio, Nicola; Macarulla, Teresa; Hitre, Erika; Hammel, Pascal; Hendifar, Andrew E.; Bates, Susan E.; Li, Chung-Pin; Hingorani, Sunil R.; de la Fouchardiere, Christelle; Kasi, Anup; Heinemann, Volker; Maraveyas, Anthony; Bahary, Nathan; Layos, Laura; Sahai, Vaibhav; Zheng, Lei; Lacy, Jill; Park, Joon Oh; Portales, Fabienne; Oberstein, Paul; Wu, Wilson; Chondros, Dimitrios und Bullock, Andrea J. (2020): Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. In: Journal of Clinical Oncology, Bd. 38, Nr. 27: S. 3185-3196

Abstract

PURPOSE To evaluate the efficacy and safety of pegvorhyaluronidase alfa (PEGPH20) plus nab-paclitaxel/gemcitabine (AG) in patients with hyaluronan-high metastatic pancreatic ductal adenocarcinoma (PDA). PATIENTS AND METHODS HALO 109-301 was a phase III, randomized, double-blind, placebo-controlled study. Patients >= 18 years of age with untreated, metastatic, hyaluronan-high PDA were randomly assigned 2:1 to PEGPH20 plus AG or placebo plus AG. Treatment was administered intravenously in 4-week cycles (3 weeks on, 1 week off) until progression or intolerable adverse events: PEGPH20 3.0 mu g/kg twice per week for cycle 1 and once per week thereafter;nab-paclitaxel 125 mg/m(2) once per week;and gemcitabine 1,000 mg/m(2) once per week. The primary end point was overall survival (OS);secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety. Response was independently assessed per RECIST v1.1. RESULTS At data cutoff, 494 patients were randomly assigned, with 492 (327 for PEGPH20 and 165 for placebo) included in intention-to-treat analyses. Baseline characteristics were balanced for PEGPH20 plus AG versus placebo plus AG. There were 330 deaths, with a median OS of 11.2 months for PEGPH20 plus AG versus 11.5 months for placebo plus AG (hazard ratio [HR], 1.00;95% CI, 0.80 to 1.27;P = .97);median PFS was 7.1 months versus 7.1 months (HR, 0.97 [95% CI, 0.75 to 1.26]);ORR was 47% versus 36% (ORR ratio, 1.29 [95% CI, 1.03 to 1.63]). Grade >= 3 adverse events with a >= 2% higher rate with PEGPH20 plus AG than with placebo plus AG included fatigue (16.0% v 9.6%), muscle spasms (6.5% v 0.6%), and hyponatremia (8.0% v 3.8%). CONCLUSION The addition of PEGPH20 to AG increased the ORR but did not improve OS or PFS. The safety profile of PEGPH20 plus AG was consistent with that found in previous studies. These results do not support additional development of PEGPH20 in metastatic PDA. (C) 2020 by American Society of Clinical Oncology

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0732-183X
• Sprache: Englisch